Non-small cell lung cancer

Available tests Fluorescence in situ hybridisation analysis of FFPE tissue sections for: ALK t(2p23;) rearrangement; ROS1 t(6q22;) rearrangement; MET (7q31) copy number/ratio
Clinical details: 
The determination of ALK stsus in patients with lung cancer is critical in the identification of patients eligible for ALK inhibitor therapy. Patients with ROS1 rearrangement have also been shown to be sensitive to the ALK inhibitor crizotininb, and MET amplification may contribute to acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI's), and may be a target for MET inhibitors.
Synonyms or keywords: 
ALK, ROS1, MET, crizotininb, Xalkori, lung cancer, non-small cell lung cancer, adenocarcinoma, NSCLC
Sample type and Volume required: 
FFPE tissue sections – 3-4µm sections on unstained Apes slides with appropriate IHC/H&E slide for correlation
Turnaround time: 
Current service turnaround times: Urgent 2-7 calendar days; Non-urgent 5-10 calendar days; National targets: Urgent samples 95% reported within 14 days; Non-urgent 95% reprted within 21 days
Oncology Cytogenetics Laboratory at Guy's Hospital
Genetics Department
Tower Wing - 5th Floor
Guy's Hospital
Great Maze Pond
London SE1 9RT

T: 020 7188 1715
For clinical advice or interpretation of results, please contact the laboratory in the first instance.

Print as a PDF

Last updated: 07/08/2015